Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Non-Current Deffered Revenue (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Non-Current Deffered Revenue for 11 consecutive years, with $8.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue fell 21.2% year-over-year to $8.8 million, compared with a TTM value of $8.8 million through Sep 2025, down 21.2%, and an annual FY2024 reading of $10.5 million, down 21.57% over the prior year.
  • Non-Current Deffered Revenue was $8.8 million for Q3 2025 at Tandem Diabetes Care, down from $9.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $19.1 million in Q3 2022 and bottomed at $8.8 million in Q3 2025.
  • Average Non-Current Deffered Revenue over 5 years is $13.8 million, with a median of $13.7 million recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue decreased 0.39% in 2022, then decreased 26.4% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $16.9 million in 2021, then decreased by 0.39% to $16.9 million in 2022, then fell by 21.0% to $13.3 million in 2023, then dropped by 21.57% to $10.5 million in 2024, then fell by 15.61% to $8.8 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for TNDM at $8.8 million in Q3 2025, $9.6 million in Q2 2025, and $9.9 million in Q1 2025.